So there is a research report I found which says that a certain dose of oral Ketamine can help within 2 weeks for depression (or up to 6 weeks...). The dose is based on body weight. The papers also said that this is more of a useful and less pricey way of using Ketamine (and to note: USA Ketamine clinics have been also/or instead offering oral ketamine rather than infusions during Covid times). It does seem to have less efficacy than infusions, but there is still a percentage of people who get great benefit from it. Here's the research I found:
This article is also really interesting as it says Tramadol helps Ketamine work better...., but it relates to rats which we know aren't the same as humans!: https://pubmed.ncbi.nlm.nih.gov/23124884/
I am going to try this...I'll let you all know how it goes. I won't be able to cope without adding other stuff to it, but maybe I will start waking up in the morning feeling less desperate and panicked.
Just read this: basically oral Ketamine has poor bioavailability, so that is why it is weaker than infusions:
Intravenous (IV) ketamine and even the newly approved esketamine nasal spray as options for treatment-resistant depression are costly and difficult to implement, prompting interest in oral ketamine, despite its poor 20% bioavailability. These investigators reviewed evidence on oral ketamine in depressed patients from two small randomized, controlled trials (RCTs; 68 patients receiving ketamine; 1 RCT of depressed patients with chronic headache) and several uncontrolled studies (1 prospective study of depressed hospice patients, n=14; 10 case reports or series or chart reviews, n=141).
So maybe I will snort it or put it under my tongue.
2 final papers, both quite hopeful:
www.nature.com
www.cambridge.org
- There is a paper which states that previous trials have found around a 50% efficacy: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2359-1
- This paper is with less efficacy (30%) - but all of these cases were treatment-resistant depression: https://journals.lww.com/psychophar..._in_treatment_resistant_depression__a.16.aspx
- This paper which reviews the research says it takes between 2-6 weeks with good tolerability: https://pubmed.ncbi.nlm.nih.gov/30995364/
These findings suggest that if ketamine is to find a place as an off-label treatment for depression and suicidality in mainstream psychiatry, researchers should study the safety, efficacy, and optimization of oral ketamine. Intravenous and intranasal routes may be monetarily more promising, but the oral route could be of greatest service. (that's from https://pubmed.ncbi.nlm.nih.gov/30997961/ )
*Here is a reassuring quote from another paper:Besides, data from chronic pain management indicate that oral ketamine can often be safely used for longer periods of time, including at home (https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2359-1)
*Here's another paper: https://pubmed.ncbi.nlm.nih.gov/30946543/This article is also really interesting as it says Tramadol helps Ketamine work better...., but it relates to rats which we know aren't the same as humans!: https://pubmed.ncbi.nlm.nih.gov/23124884/
I am going to try this...I'll let you all know how it goes. I won't be able to cope without adding other stuff to it, but maybe I will start waking up in the morning feeling less desperate and panicked.
Just read this: basically oral Ketamine has poor bioavailability, so that is why it is weaker than infusions:
Intravenous (IV) ketamine and even the newly approved esketamine nasal spray as options for treatment-resistant depression are costly and difficult to implement, prompting interest in oral ketamine, despite its poor 20% bioavailability. These investigators reviewed evidence on oral ketamine in depressed patients from two small randomized, controlled trials (RCTs; 68 patients receiving ketamine; 1 RCT of depressed patients with chronic headache) and several uncontrolled studies (1 prospective study of depressed hospice patients, n=14; 10 case reports or series or chart reviews, n=141).
So maybe I will snort it or put it under my tongue.
2 final papers, both quite hopeful:
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study - Translational Psychiatry
Recently, low-dose ketamine has been proposed as a rapid-acting treatment option for suicidality. The majority of studies to date have utilised intravenous (IV) ketamine, however, this route of administration has limitations. On the other hand, oral ketamine can be administered in a range of...
www.nature.com
Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study | The British Journal of Psychiatry | Cambridge Core
Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study - Volume 214 Issue 1
Last edited:
